After more than a decade leading microbiome drug research, Vedanta Biosciences is cutting 20% of its workforce following a failed Phase 2 trial of its IBD therapy VE202. CEO Bernat Olle admitted the results were humbling — the drug showed no significant benefit over placebo for ulcerative colitis. While this setback mirrors earlier failures from peers like Seres Therapeutics, Olle insists every study provides data that can guide the field forward. Vedanta will now shift focus to areas where microbiome therapies are proving viable — most notably its Phase 3 drug VE303 for recurrent C. diff infections. With over $300M…
Author: Abhay Panchal
Freestanding GI centers are fighting tight margins, shrinking reimbursements, and rising costs. Yet, some are thriving. According to Dr. Nalini Guda, success comes down to a blend of operational discipline and smart growth strategies — from cutting room turnover times to just minutes, to exploring new revenue streams like endoscopic ultrasound outside hospitals. Technology, staffing efficiency, smarter scheduling, and cost negotiations all play a role, but profitability isn’t automatic. It requires relentless focus on workflows and innovation. The question: which centers will adapt fast enough to capture the next wave of GI volume growth?
As hospital consolidation accelerates, Paul Berggreen, MD — president of the American Independent Medical Practice Association and CSO of GI Alliance — warns that independent gastroenterology groups are at risk of collapse without systemic reforms. In an interview with Becker’s, Dr. Berggreen outlined five critical changes.
Annabel Kartal Allen reports that Novo Nordisk’s blockbuster weight loss drug Wegovy (semaglutide) has received accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver scarring. This milestone makes it the first GLP-1 receptor agonist approved for this indication. The approval stems from the Phase III ESSENCE trial, where Wegovy resolved steatohepatitis in 63% of patients compared with 34% on placebo and showed notable improvements in liver fibrosis. Full approval depends on ongoing trial data.
Once an academic curiosity, artificial intelligence (AI) has moved from computational labs into the endoscopy suite, most notably with computer-aided detection systems for polyp detection. Gastroenterology’s special issue examines how AI is transforming care delivery, the challenges it raises, and the importance of keeping patients at the center of innovation. Issue editors Dennis Shung, MD (Yale University), and Marietta Iacucci, MD (University College Cork), have selected articles that address patient perspectives, ethical considerations, and the latest advances in AI for detection, diagnosis, and disease management.
While gastrointestinal (GI) endoscopy is rarely performed during pregnancy—accounting for just 0.4% of procedures—there are times when it is urgently needed. A new review by physician-scientists from Beth Israel Deaconess Medical Center (BIDMC), published in the American Journal of Gastroenterology, offers experience-informed and, where possible, evidence-based recommendations to guide gastroenterologists in providing safe, effective care to pregnant patients when endoscopy can’t wait.
Hospitals and insurance reporter Tara Bannow details how the Department of Justice and several states have reached a proposed settlement allowing UnitedHealth Group to acquire Amedisys — but only if they divest 164 home health and hospice locations in 19 states. The DOJ had sued to block the deal, warning it could harm competition in the home health and hospice sector. Under the agreement, the divested sites — representing about $528 million in annual revenue — will go to BrightSpring Health Services and The Pennant Group. The settlement avoids a trial but still needs a judge’s approval.
Harry Severance, MD warns that almost 800 U.S. hospitals are now at extreme risk of closure—a number that keeps rising with each new report. Many of these facilities serve as the sole lifeline for rural and disadvantaged communities, yet face crippling challenges: inadequate reimbursements, staff shortages, and selective underpayment to certain hospital settings. Severance draws a sharp analogy to the Titanic disaster—leaders aware of looming dangers but distracted by other priorities, assuming the system is “too big to fail.” He cautions that ignoring these warning signs could push the nation’s healthcare infrastructure toward a similar fate, leaving millions without access…
Sonic Incytes Medical Corp has secured FDA 510(k) clearance for Velacur ONE™, an AI-guided point-of-care ultrasound elastography device aimed at diagnosing and monitoring chronic liver diseases like MASLD and MASH. Building on its predecessor, Velacur™, the new model offers improved portability, a refined interface, and advanced features such as B-mode imaging and AI-based organ overlay for precise liver localization. The device measures attenuation, VDFF (Velacur Determined-Fat Fraction), and liver stiffness, combining these metrics to aid in early detection and treatment monitoring. VDFF technology, cleared in 2024, shows strong correlation with MRI-PDFF—the gold standard for liver fat measurement—and enables higher reimbursement…
Self-employed gastroenterologists can see substantial salary growth over the course of their careers, according to data from Medscape’s salary explorer. Nationwide, those with one to seven years of experience earn an average of $410,000 annually. That figure rises steadily with experience: That marks a 41% increase from early to mid-career compensation — followed by a plateau, with earnings remaining steady from 15 to 28 years of experience.